Purpose:To explore the effect of anti-FasL on ADM resistance of K562/ADM cell subline and its possible mechanism.Methods:Control group,untreated with VER or anti-FasL ,VER-treated group,anti-FasL-treated group and anti-FasL +VER-treated group were set up. MTT、FCM、TUNEL、S-P immunechemistry and RT-PCR assay were used for detection.Results:Anti-FasL or VER treatment was capable of strengthening sensitivity of K562/ADM cells to ADM,ID 50 of anti-FasL and VER was 200ng/ml and 6?g/ml,respectively;DNA content of apoptosis from cycling analysis curve of K562/ADM cell was 7.42%,32.10%,49.29%,56.26%,respectively,and positive rate in situ apoptosis was 4.5%,36%,45%,58%,respectively,which represented a tendency of gradual increase. Anti-FasL was capable of effecting FasL and bcl-2 expression,but not Pgp.Conclusions:Anti-FasL alone or synergically with VER was capable of reversing ADM resistance of K562/ADM cell,which may be used as a novel reversor of multidrug resistance.

BACKGROUNDTo investigate the clinical value of serum total MMP-9 detection in lung malignancies.

METHODSSerum total MMP-9 levels were detected in 63 patients with lung malignancies by sandwich ELISA with monoclonal antibody against human total MMP-9.

RESULTSSerum total MMP-9 was (92.2± 74.39) μg/L in lung malignancy group, which was significantly higher than that of healthy control [(9.5± 6.74) μg/L](P < 0.05). In lung cancer group, there were significant differences in serum total MMP-9 level between patients with and without lymph node metastasis, and between progressive disease+death group and complete response+partial response group. Significantly negative correlation was observed between serum CA242 and serum total MMP-9 levels (P=0.021).

CONCLUSIONSDetection of serum total MMP-9 may be helpful to predict metastasis and treatment response of lung cancer.